BFM
VRTX icon

Boston Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Boston Financial Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$904K Hold
2,244
– – 0.03% 200
2024
Q3 		$1.04M Hold
2,244
– – 0.03% 189
2024
Q2 		$1.05M Hold
2,244
– – 0.03% 186
2024
Q1 		$938K Hold
2,244
– – 0.03% 202
2023
Q4 		$913K Hold
2,244
– – 0.03% 200
2023
Q3 		$780K Buy
+2,244
New +$785K 0.03% 194

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Boston Financial Management's VRTX Position: Q4 2024 in Review

Boston Financial Management held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2024 at 2,244 shares worth $904K. The position accounts for 0.03% of the portfolio, ranked #200.

Boston Financial Management first reported a position in VRTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $1.05M in Q2 2024. 1,558 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Boston Financial Management held 2,244 shares of Vertex Pharmaceuticals worth $904K as of Q4 2024.
  • Boston Financial Management left its Vertex Pharmaceuticals share count unchanged in Q4 2024.
  • Vertex Pharmaceuticals made up 0.03% of Boston Financial Management's portfolio in Q4 2024, its #200 holding.
  • Boston Financial Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
  • Boston Financial Management's Vertex Pharmaceuticals position peaked at $1.05M in Q2 2024.
  • 1,558 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Boston Financial Management's 13F filing for Q4 2024, filed 3 Feb 2025.